Emmessar Biotech & Nutrition
Emmessar Biotech & Nutrition (EMMESSA) share price was ₹22.74 at the 28 Oct 2026 close; market capitalisation ₹11.32 Cr; P/E (TTM) 29.15; sector Chemicals. The share price fell 25.3% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue was ₹0.06 Cr, against ₹0.09 Cr a year earlier and net profit was ₹0.13 Cr, against ₹0.17 Cr a year earlier (compared with Jun 2025). Promoters held 59.53% of Emmessar Biotech & Nutrition in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 48/100 (Average) as of 28 Oct 2026.
Key Fundamentals
MicrocapChemicals & PetrochemicalsChemicalsPrice-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM
Peer Comparison
Commodities › Chemicals › Commodity Chemicals
| ₹2,354.00 | 32.28 | 69,778 Cr | 4.56 | 0.21% | 13.07% | 14.64% | 17,997 Cr | 2,162 Cr | |
| ₹601.45 | — | 15,322 Cr | 0.72 | 1.84% | -7.73% | -2.69% | 15,521 Cr | -1,971 Cr | |
| ₹1,177.20 | 15.10 | 14,861 Cr | 2.17 | 0.84% | 9.90% | 11.30% | 12,189 Cr | 984 Cr | |
| ₹515.00 | 7.30 | 7,567 Cr | 0.83 | 4.12% | 8.75% | 10.38% | 8,860 Cr | 1,037 Cr | |
| — | 103.79 | 7,489 Cr | 10.36 | 0.13% | 18.80% | 25.38% | 725 Cr | 68 Cr | |
| ₹551.45 | 61.00 | 4,050 Cr | 0.78 | 3.20% | -0.05% | 1.29% | 4,622 Cr | 66 Cr | |
| ₹385.65 | 7.68 | 3,553 Cr | 1.00 | 3.04% | 13.30% | 16.87% | 3,138 Cr | 473 Cr | |
| Emmessar Biotech & Nutrition (this company) | — | 29.15 | 11 Cr | 1.40 | 0.00% | 5.37% | 6.36% | 2 Cr | 0 Cr |
| Median 8 companies | ₹576.45 | 29.15 | 7,528 Cr | 1.20 | 1.34% | 9.33% | 10.84% | 6,741 Cr | 271 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 98/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company is almost debt free.
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -44.4% over past five years.
- Company has a low return on equity of 6.71% over last 3 years.
Technical Indicators
Oscillators
Bullish
Overall
Neutral
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin -583% · Jun 2026
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.07 | 0.08 | 0.33 | 0.08 | 0.08 | 0.34 | 0.1 | 0.1 | 0.09 | 0.09 | 0.09 | 0.09 | 0.06 |
| Expenses | 0.35 | 0.3 | 0.54 | 0.47 | 0.36 | 0.42 | 0.38 | 0.43 | 0.36 | 0.46 | 0.43 | 0.46 | 0.41 |
| Operating Profit | -0.28 | -0.22 | -0.21 | -0.39 | -0.28 | -0.08 | -0.28 | -0.33 | -0.27 | -0.37 | -0.34 | -0.37 | -0.35 |
| OPM % | -400% | -275% | -63.64% | -487.5% | -350% | -23.53% | -280% | -330% | -300% | -411.11% | -377.78% | -411.11% | -583.33% |
| Other Income | 0.46 | 0.53 | 0.53 | 0.48 | 0.46 | 0.51 | 0.43 | 0.61 | 0.53 | 0.54 | 0.49 | 0.47 | 0.54 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 |
| PBT | 0.16 | 0.29 | 0.3 | 0.07 | 0.16 | 0.41 | 0.13 | 0.26 | 0.24 | 0.14 | 0.12 | 0.07 | 0.17 |
| Tax % | 68.75% | 31.03% | 56.67% | -285.71% | 43.75% | 31.71% | 84.62% | 126.92% | 25% | 21.43% | 8.33% | 57.14% | 17.65% |
| Net Profit | 0.05 | 0.2 | 0.13 | 0.27 | 0.09 | 0.28 | 0.02 | -0.07 | 0.17 | 0.11 | 0.12 | 0.03 | 0.13 |
| EPS (₹) | 0.1 | 0.4 | 0.26 | 0.54 | 0.18 | 0.56 | 0.04 | -0.14 | 0.34 | 0.22 | 0.24 | 0.06 | 0.26 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.19 | 1.98 | 2.61 | 1.27 | 0.63 | 3.4 | 6.99 | 0.36 | 1.02 | 0.56 | 0.61 | 0.37 | 0.33 |
| Expenses | 2.34 | 2.66 | 2.38 | 1.67 | 1.27 | 3.81 | 6.15 | 1.26 | 1.71 | 1.64 | 1.56 | 1.73 | 1.76 |
| Operating Profit | -0.15 | -0.68 | 0.23 | -0.4 | -0.64 | -0.41 | 0.84 | -0.9 | -0.69 | -1.08 | -0.95 | -1.36 | -1.43 |
| OPM % | -6.85% | -34.34% | 8.81% | -31.5% | -101.59% | -12.06% | 12.02% | -250% | -67.65% | -192.86% | -155.74% | -367.57% | -433.33% |
| Other Income | 0.06 | 0.03 | 0.98 | 1.25 | 1.01 | 1.21 | 1.47 | 1.92 | 1.75 | 1.99 | 2.01 | 2.04 | 2.04 |
| Interest | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.07 | 0.03 | 0.01 | 0.05 | 0.08 | 0.06 | 0.06 | 0.09 | 0.09 | 0.1 | 0.1 | 0.1 | 0.11 |
| PBT | -0.16 | -0.68 | 1.19 | 0.8 | 0.29 | 0.74 | 2.25 | 0.93 | 0.97 | 0.81 | 0.96 | 0.58 | 0.5 |
| Tax % | -25% | -30.88% | 0% | -15% | -82.76% | -2.7% | 36% | 48.39% | 47.42% | 7.41% | 66.67% | 24.14% | — |
| Net Profit | -0.12 | -0.47 | 1.19 | 0.91 | 0.53 | 0.75 | 1.45 | 0.48 | 0.5 | 0.75 | 0.32 | 0.44 | 0.39 |
| EPS (₹) | -0.24 | -0.94 | 2.38 | 1.82 | 1.06 | 1.5 | 2.9 | 0.96 | 1 | 1.5 | 0.64 | 0.88 | 0.78 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | -3.62 | -4.09 | -2.91 | -2.01 | -1.49 | -0.73 | 0.7 | 1.17 | 1.67 | 2.41 | 2.71 | 3.12 |
| Borrowings | 0 | 0 | 0 | 0 | 0.07 | 0 | 0 | 0 | 0.08 | 0.11 | 0 | 0 |
| Other Liabilities | 1.03 | 1.36 | 1.13 | 0.92 | 1.59 | 1.86 | 2.11 | 1.04 | 1.19 | 1.23 | 1.71 | 1.66 |
| Total Liabilities | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.42 | 9.78 |
| Fixed Assets | 1.42 | 0.73 | 0.72 | 2.25 | 1.99 | 1.91 | 1.86 | 2.07 | 2 | 1.91 | 1.81 | 1.72 |
| CWIP | 0 | 0 | 0.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Assets | 0.98 | 1.53 | 1.69 | 1.65 | 3.17 | 4.21 | 5.94 | 5.13 | 5.93 | 6.83 | 7.6 | 8.05 |
| Total Assets | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.42 | 9.78 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -0.01 | — | 0.75 | 0.74 | 0.39 | 1.03 | 0.47 | 2.27 | 0.38 | 0.64 | 0.22 | 0.27 |
| Investing | 0 | — | -0.74 | -0.69 | -0.37 | -1.06 | 0.01 | -2.61 | -0.55 | -0.64 | -0.23 | -0.26 |
| Financing | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 |
| Net Cash Flow | -0.01 | — | 0.01 | 0.05 | 0.01 | -0.03 | 0.48 | -0.34 | -0.17 | 0 | 0 | 0.02 |
| Free Cash Flow | -0.01 | — | -0.06 | -0.04 | 0.39 | 1.03 | 0.47 | 1.96 | 0.35 | 0.64 | 0.22 | 0.26 |
| CFO/OP | 7 | — | 343 | -198 | -61 | -251 | 68 | -284 | -46 | -57 | -25 | -11 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 6.67 | 66.36 | 5.59 | 8.62 | 23.17 | 3.22 | 142 | 10.14 | 3.58 | 13.04 | 11.97 | 19.73 |
| Inventory Days | 336 | 137 | 122 | 52.14 | 2,050 | 273 | 7.24 | 197 | 128 | 164 | 231 | 406 |
| Days Payable | 151 | 76.04 | 76.04 | 5.79 | 1,628 | 190 | 51.7 | 56.15 | 0 | 18.25 | 0 | 40.56 |
| Cash Conversion Cycle | 192 | 127 | 51.22 | 54.97 | 444 | 86.18 | 97.05 | 151 | 131 | 159 | 242 | 385 |
| Working Capital Days | 38.33 | 22.12 | 85.31 | 175 | 458 | 30.06 | 79.37 | -60.83 | 115 | 91.25 | 29.92 | 88.78 |
| ROCE % | -10.81% | -39.3% | 80% | 31.5% | 17.66% | 25.48% | 45.14% | 15.67% | 15.02% | 11.35% | 12.61% | 7.33% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Emmessar Biotech & Nutrition insights
60 extracted metrics + investor summaries across FY09–FY27.
Documents
Frequently Asked Questions about Emmessar Biotech & Nutrition
What does Emmessar Biotech & Nutrition Ltd do?
Where is Emmessar Biotech & Nutrition Ltd (EMMESSA) listed?
Which sector does Emmessar Biotech & Nutrition Ltd belong to?
What is the market capitalisation of Emmessar Biotech & Nutrition Ltd?
What is the PE ratio of Emmessar Biotech & Nutrition Ltd?
What is the 52-week high and low of Emmessar Biotech & Nutrition Ltd?
What is the Return on Equity (ROE) of Emmessar Biotech & Nutrition Ltd?
Company Information
Emmessar Biotech & Nutrition Ltd is a standalone healthcare-products and property-leasing company. It manufactures /trades a small VedaCeuticals portfolio and earns rent from sub-leasing its MIDC Taloja industrial land; FY26 filings report Healthcare and Rent on Leasehold Land as the only operating segments.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524768.md for Emmessar Biotech & Nutrition Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.